Common antibiotics are steadily losing their power against infections in Indian hospitals, the Indian Council of Medical Research (ICMR) has warned in its latest surveillance report, with several familiar bacteria no longer responding to medicines doctors have routinely used for years.
The ICMR's Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025 gives an overview of how well different antibiotics are working against bacteria found in hospitals across the country. Its findings point to a worrying trend: commonly used antibiotics are becoming less effective against familiar infections, while some bacteria are also resisting even the stronger medicines doctors rely on for serious infections.
The report examined 1,13,008 positive laboratory samples from 30 large, specialised hospitals in 2025. For the first time, it also included data from 34 smaller, secondary-care hospitals, including 12 district hospitals, which contributed another 20,529 positive samples.
The most commonly found bacteria in the larger hospitals was Escherichia coli (E. coli), which accounted for 24.4 per cent of the samples. It was followed by Klebsiella pneumoniae (16.9 per cent), Pseudomonas aeruginosa (12.2 per cent) and Acinetobacter baumannii (9.5 per cent).
E. coli emerges as the biggest concern
The problem is particularly serious with E. coli, a bacterium that lives in the intestines but can cause urinary tract infections and sometimes serious bloodstream and intestinal infections. The report found that only 18.4 per cent of the tested samples responded to cefotaxime and 24.7 per cent to ceftazidime, two commonly used antibiotics. Just 9 per cent responded to ciprofloxacin.
In simple terms, these medicines may not work against a large number of E. coli infections in the hospitals covered by the report.
Klebsiella pneumoniae presents a similar challenge. In 2025, only 36.5 to 40.4 per cent of the tested samples responded to carbapenems, a group of powerful antibiotics often used to treat serious infections when other medicines fail. The response was even lower among samples collected from intensive-care units, which means treatment can become more difficult, recovery may take longer and doctors may have fewer medicines to choose from.
Hospital infections harder to treat
Some of the report's most worrying findings relate to bacteria commonly found in serious hospital infections. The report found that 91.1 per cent of the tested A. baumannii samples showed resistance to carbapenems, leaving doctors with fewer treatment options, particularly in intensive-care units.
The report also found that 56.8 per cent of the tested Staphylococcus aureus samples were resistant to methicillin, an antibiotic. Although some medicines continued to work well in laboratory tests, resistance to other antibiotics, including linezolid, was also reported.
That is why preventing infections in hospitals is now just as important as treating them, the report says. Regular handwashing, proper cleaning of hospital equipment and surfaces, sterilisation of medical instruments and precautions to prevent infections from spreading can all help control the problem.
Resistance reaches smaller hospitals
One important development in the 2025 report is the wider picture it gives beyond large, specialised hospitals. The findings show that antibiotic resistance is a concern at different levels of healthcare, although the types of bacteria found and their resistance patterns vary.
In smaller hospitals, E. coli was commonly found, particularly in urine samples. Larger hospitals reported a wider variety of bacteria, including higher numbers of Klebsiella, Pseudomonas and Acinetobacter. These differences may be linked to the types of patients treated, the seriousness of their illnesses and their exposure to the hospital environment.
The report also cautions against routinely using fluoroquinolones to treat certain bacterial diarrhoeal infections without considering local resistance patterns. Only 7.5 per cent of the tested Shigella flexneri samples and 8.9 per cent of Shigella sonnei samples responded to ciprofloxacin, while among the tested types of E. coli that cause diarrhoea, just 0.7 per cent responded to ciprofloxacin and only 4.6 per cent to cefixime.
Newborns at risk, and what needs to change
Antibiotic resistance is particularly worrying when it affects newborn babies and critically ill patients, who are more vulnerable to infections. For the first time, the report provides separate findings on bloodstream infections among newborns, infants and children.
Among newborns aged 0 to 28 days, Klebsiella pneumoniae was the most commonly identified bacterium, accounting for 25.1 per cent of the tested samples. Candida, a type of fungus, and Acinetobacter baumannii were also commonly found. Several important bacteria causing infections in newborns were responding poorly to commonly used antibiotics, including third-generation cephalosporins.
For a newborn with suspected sepsis, a serious infection that can spread through the bloodstream, starting the right treatment quickly is extremely important. But when the bacteria causing the infection are resistant to commonly used medicines, doctors face a more difficult task, which makes timely diagnosis, reliable laboratory testing and strict infection-control practices especially important in newborn care.
The report highlights the need for a more careful and responsible approach to antibiotic use. Doctors need access to timely laboratory tests that can identify the bacteria causing an infection and show which antibiotics are likely to work against it, so that treatment can be changed when necessary.
Hospitals also need to make responsible antibiotic use a regular part of patient care. Medicines such as carbapenems need particular protection because they may be among the few remaining options for some serious infections.
Not every finding was bleak. Salmonella Typhi, the bacterium that causes typhoid, continued to respond well to several tested medicines, including azithromycin and ceftriaxone. The report's message is that doctors cannot simply assume an antibiotic that worked well in the past will continue to work, and the right medicine depends on the bacteria causing the infection and the medicines it is still sensitive to.